Committee Composition

Michael H. Tardugno

Mr. Tardugno's career has been exclusively focused in healthcare and brings over 29 years of experience in the pharmaceutical and medical device industries to Celsion. He has held positions of increasing responsibility in general management, operations, and product and technology development. Prior to joining the company in 2007, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies,Inc., a subsidiary of Mylan Laboratories, a transdermal delivery system and medical components company. Before Mylan, he was a founding member of management and Executive Vice President of Songbird Hearing, Inc., a privately held start-up company. Before Songbird, he held the positions of Senior Vice President of Technical Operations, World Wide for the ConvaTec division of Bristol-Myers Squibb, and World Wide Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations and as plant manager for the company's Ross Laboratories Division nutritional business. Mr. Tardugno holds a B.S. in biology with a chemistry concentration from St. Bonaventure University and attended the Harvard Business School executive program.

Recent Stock Transactions by Michael H. Tardugno
Date Type Shares Traded Price Range
Oct 7, 2016 Buy 10,000 1.14
Aug 16, 2016 Buy 5,000 1.25
Jun 16, 2016 Buy 7,500 1.35
Feb 19, 2016 Buy 3,000 1.27
Feb 17, 2016 Buy 2,000 1.27
Feb 16, 2016 Buy 4,500 1.20
Feb 12, 2016 Buy 6,500 1.13
Feb 2, 2016 Acquisition (Non Open Market) 25,000 1.33
Aug 10, 2015 Buy 5,000 2.29
Aug 15, 2014 Buy 4,000 3.12
Jun 20, 2014 Acquisition (Non Open Market) 12,000 3.50
Jun 11, 2014 Buy 5,000 3.20
Mar 14, 2014 Buy 4,000 3.84
Nov 19, 2013 Buy 2,800 3.59
Aug 16, 2013 Buy 5,000 1.08
Jun 12, 2013 Buy 10,000 1.35
Dec 7, 2012 Option Execute 17,271 2.77
Sep 14, 2012 Buy 5,000 5.03 - 5.04
Dec 5, 2011 Buy 5,000 2.16 - 2.21
May 26, 2011 Buy 17,271 2.77
Mar 23, 2011 Acquisition (Non Open Market) 17,083 2.40
May 7, 2010 Buy 4,000 3.95
Feb 19, 2010 Acquisition (Non Open Market) 17,412 2.94
Jan 19, 2010 Option Execute 16,667 n/a
Nov 19, 2009 Buy 6,000 3.21
Aug 17, 2009 Buy 5,000 3.30
Mar 17, 2009 Buy 3,750 2.56
Jan 19, 2009 Acquisition (Non Open Market) 25,000 2.72
Nov 14, 2008 Buy 3,000 2.83
Jun 16, 2008 Acquisition (Non Open Market) 2,500 4.38 - 4.40
May 17, 2007 Buy 2,384 4.81 - 4.82
Feb 23, 2007 Buy 7,616 3.46
Dr. Augustine Chow

Dr. Augustine Chow was appointed to the Board of Directors in March 2007.  Dr. Chow is the Chairman of Harmony Asset Management Limited in Hong Kong as well as a Director of Medifocus Inc. (TSX Venture: MFS).  From 1996-2015, Dr. Chow was the Chief Executive Officer of Harmony Asset Limited, a Hong Kong listed investment company. Between 2008 and 2016 he served as Executive Director of Kaisun Energy Group Limited.  From 1990 to 1998, Dr. Chow was the Chief Executive Officer of Allied Group of Companies based in Hong Kong which included a number of publicly-listed companies spanning various industries.  Prior to this, Dr. Chow held a senior position with Brunswick Corporation and Outboard Marine Corporation and was responsible for all business activities in South East Asia and China.  Dr. Chow has extensive experience in managing publicly-listed companies that are involved in manufacturing, marketing and financial services.  He specializes in mergers and acquisitions.  Dr. Chow’s qualifications include a number of Bachelors, Masters and Doctoral degrees.  Among these are a MSc from London Business School, a PhD from the University of South Australia, and an Engineering Doctorate and PhD on Biology from City University of Hong Kong.

Recent Stock Transactions by Dr. Augustine Chow
Date Type Shares Traded Price Range
Jun 30, 2016 Acquisition (Non Open Market) 7,539 1.27
Feb 2, 2016 Acquisition (Non Open Market) 5,000 1.33
May 26, 2011 Buy 34,542 2.77
Robert W. Hooper

Mr. Hooper currently serves as President of Crows Nest Ventures, Inc. and provides advisory and consulting services to the health care industry. From 1997-2001 he served as President North America for IMS Health, the global leader in health care information and market research. From 1993-1997 Mr. Hooper served as President of Abbott Laboratories Canada, based in Montreal. From 1989-1993 he served as Managing Director, Australia/Asia for Abbott Laboratories. Prior to 1989 Mr. Hooper served as Director of Manufacturing and Plant Manager for Abbott's Nutritional and Hospital Products Divisions. Mr. Hooper began his career with E.R. Squibb and Sterling Winthrop Labs. He received a B.A. in Biology from Wilkes University and currently resides in Naples, FL with his wife Cynthia.

Recent Stock Transactions by Robert W. Hooper
Date Type Shares Traded Price Range
Feb 2, 2016 Acquisition (Non Open Market) 5,000 1.33
Nov 13, 2014 Buy 4,000 2.50
Nov 15, 2012 Buy 11,600 5.20
Sep 10, 2012 Buy 10,000 4.92 - 4.97
Aug 29, 2012 Buy 2,500 4.65
May 19, 2012 Buy 4,520 1.77
Mar 21, 2012 Buy 4,500 1.95
Dec 6, 2011 Buy 9,510 2.10
Dec 5, 2011 Buy 490 2.10
Aug 16, 2011 Buy 5,000 3.00
Jun 13, 2011 Buy 8,000 3.10
May 26, 2011 Buy 25,907 2.77
Mar 23, 2011 Acquisition (Non Open Market) 5,000 2.40
Aug 10, 2010 Buy 3,000 3.35
Dr. Alberto Martinez

Dr. Alberto Martinez most recently served as the President and Chief Executive Officer of Talecris Biotherapeutics, one of the leading producers of plasma-derived therapeutic proteins in the world. Prior to joining Talecris, Dr. Martinez served as Executive Vice President of Worldwide Commercial Operations for CSL Behring, the company formed with the acquisition of Aventis Behring by Australian company CSL in 2004. He was Vice President and General Manager for Emerging Markets for Aventis Behring from 1996-2000 and served as President of Aventis BioServices from 2000-2004. Dr. Martinez began his career with Sandoz Ltd., today Novartis. He spent twenty years working with the company in a variety of roles across the world, such as Director and Head of Corporate Strategic Planning in the United States, Head of the Latin America Business Operations in Switzerland, Director of Marketing and Sales in Spain, and Head of Marketing and Clinical Research in Brazil. Dr. Martinez is originally from Brazil and holds an MD from the University of Sao Paulo.

Recent Stock Transactions by Dr. Alberto Martinez
Date Type Shares Traded Price Range
Feb 21, 2017 Buy 35,000 0.23
Feb 15, 2017 Buy 45,000 0.22
Nov 14, 2016 Buy 10,000 0.86
Nov 11, 2016 Buy 10,000 0.91
Aug 16, 2016 Buy 5,000 1.25
Jun 17, 2016 Buy 5,000 1.35
Feb 16, 2016 Buy 5,000 1.16
Feb 2, 2016 Acquisition (Non Open Market) 5,000 1.33
May 13, 2015 Buy 5,000 2.50
Aug 15, 2014 Buy 5,000 3.12
Jun 26, 2014 Buy 5,000 3.36
Jun 11, 2014 Buy 5,000 3.20
Aug 16, 2013 Buy 5,000 1.07
May 21, 2013 Buy 5,000 0.93
May 21, 2013 Buy 5,000 0.93
May 13, 2013 Buy 5,000 0.96
May 10, 2013 Buy 5,000 0.92
Mar 20, 2013 Buy 3,750 1.06
Dec 5, 2012 Option Execute 34,583 3.25
Oct 15, 2012 Option Execute 37,042 2.36 - 2.77
Dec 20, 2011 Buy 5,000 1.77 - 1.80
Dec 15, 2011 Buy 5,875 1.80
Dec 6, 2011 Buy 5,000 2.31
May 26, 2011 Buy 34,542 2.77
Mar 23, 2011 Acquisition (Non Open Market) 34,583 2.40
Frederick J. Fritz

Mr. Fritz is currently the CEO & Founder of NeuroDx, a development stage diagnostic device company focused on the neurosurgery market. Mr. Fritz joined NeuroDx from Valeo Medical, a biotech company he founded in 2003 to develop the world's first non-invasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, a medical device spin out of Sarnoff Corp. He is a University of Illinois engineer (summa cum laude) and a Harvard MBA. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough's Wesley Jessen in 1985 as VP Marketing and Sales in 1986. He was promoted to general manager of Schering's Over the Counter pharmaceutical business in 1988 and of the podiatric products business in 1990. He was President of Coleman North America from 1995-1997. He lives outside Princeton NJ with his wife, Helen, and two teenage daughters, Erika and Jenna.

Recent Stock Transactions by Frederick J. Fritz
Date Type Shares Traded Price Range
Jun 30, 2016 Acquisition (Non Open Market) 7,539 1.27
Feb 2, 2016 Acquisition (Non Open Market) 5,000 1.33
Dec 18, 2014 Buy 4,000 2.34
Aug 14, 2014 Buy 4,000 3.20
Jun 11, 2014 Buy 5,000 3.20
Mar 14, 2014 Buy 2,500 3.86
Feb 26, 2014 Acquisition (Non Open Market) 4,500 3.72
Nov 15, 2013 Buy 3,000 3.80
Aug 16, 2013 Buy 10,000 1.09
Mar 20, 2013 Buy 20,000 1.06
May 17, 2012 Buy 5,000 1.93
Mar 19, 2012 Buy 4,000 1.86
Dec 7, 2011 Buy 5,000 2.07
Dec 6, 2011 Buy 5,000 2.31
Jul 8, 2011 Statement of Ownership 0 n/a
Donald Braun Ph.D.

Dr. Braun joined Celsion in 2015 and brings over 30 years of research expertise in oncology, with a focus on immunotherapy and the effectiveness and impact of chemotherapy protocols on various cancers and tumor types. Prior to his retirement in 2016 Dr. Braun served as Vice President Translational Research and Chief Science Officer at the Cancer Treatment Centers of America. Prior to the CTCA, he was the Scientific Director of the Cancer Center and Professor of Medicine and Immunology at Rush Medical College in Chicago, and the Administrative Director of the Cancer Institute and a Professor of Surgery with tenure at the Medical College of Ohio.  Dr. Braun has been appointed to and served on more than a dozen federal government and public advisory committees on oncology and immunology. He received his Ph.D. in Immunology and Microbiology from the University of Illinois at the Medical Center in Chicago.

Recent Stock Transactions by Donald Braun Ph.D.
Date Type Shares Traded Price Range
Feb 2, 2016 Acquisition (Non Open Market) 5,000 1.33
Andreas Voss MD

Dr. Voss joined Celsion in 2015 and currently serves as Vice President of Clinical Affairs in Europe at Caris Life Sciences, a biotechnology company focused on implementing personalized medicine in oncology through its liquid biopsy technology. Prior to joining Caris in 2010, he was responsible for the global clinical development of Avastin® and a member of the Corporate Drug Safety Board at F. Hoffmann-La Roche. Before joining Roche in 2006, he was Medical Director for the Lung Cancer Disease Area at AstraZeneca, and from 2000 to 2003, he was the Medical Director for Anti-infectives and Oncology atBayer GmbH.  From 1996 to 2000, Dr. Voss was Head of Medical Research, Oncology at Asta Medica AG. Dr. Voss received his M.D. from the University of Hamburg Medical School and was a postdoctoral fellow at the University of California at San Diego. He is board certified in internal medicine

Recent Stock Transactions by Andreas Voss MD
Date Type Shares Traded Price Range
Feb 2, 2016 Acquisition (Non Open Market) 5,000 1.33

Stock transaction information provided by EDGAR Online. Celsion Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

  Audit Compensation Nominating and Governance Science and Technology
Dr. Augustine Chow
Image of Dr. Augustine Chow
Dr. Augustine Chow
Director
Director Since 3/1/2007

Dr. Augustine Chow was appointed to the Board of Directors in March 2007.  Dr. Chow is the Chairman of Harmony Asset Management Limited in Hong Kong as well as a Director of Medifocus Inc. (TSX Venture: MFS).  From 1996-2015, Dr. Chow was the Chief Executive Officer of Harmony Asset Limited, a Hong Kong listed investment company. Between 2008 and 2016 he served as Executive Director of Kaisun Energy Group Limited.  From 1990 to 1998, Dr. Chow was the Chief Executive Officer of Allied Group of Companies based in Hong Kong which included a number of publicly-listed companies spanning various industries.  Prior to this, Dr. Chow held a senior position with Brunswick Corporation and Outboard Marine Corporation and was responsible for all business activities in South East Asia and China.  Dr. Chow has extensive experience in managing publicly-listed companies that are involved in manufacturing, marketing and financial services.  He specializes in mergers and acquisitions.  Dr. Chow’s qualifications include a number of Bachelors, Masters and Doctoral degrees.  Among these are a MSc from London Business School, a PhD from the University of South Australia, and an Engineering Doctorate and PhD on Biology from City University of Hong Kong.

   
Robert W. Hooper
Image of Robert W. Hooper
Robert W. Hooper
Director
Director Since 8/01/2010

Mr. Hooper currently serves as President of Crows Nest Ventures, Inc. and provides advisory and consulting services to the health care industry. From 1997-2001 he served as President North America for IMS Health, the global leader in health care information and market research. From 1993-1997 Mr. Hooper served as President of Abbott Laboratories Canada, based in Montreal. From 1989-1993 he served as Managing Director, Australia/Asia for Abbott Laboratories. Prior to 1989 Mr. Hooper served as Director of Manufacturing and Plant Manager for Abbott's Nutritional and Hospital Products Divisions. Mr. Hooper began his career with E.R. Squibb and Sterling Winthrop Labs. He received a B.A. in Biology from Wilkes University and currently resides in Naples, FL with his wife Cynthia.

     
Dr. Alberto Martinez
Image of Dr. Alberto Martinez
Dr. Alberto Martinez
Director
Director since 12/06/2010

Dr. Alberto Martinez most recently served as the President and Chief Executive Officer of Talecris Biotherapeutics, one of the leading producers of plasma-derived therapeutic proteins in the world. Prior to joining Talecris, Dr. Martinez served as Executive Vice President of Worldwide Commercial Operations for CSL Behring, the company formed with the acquisition of Aventis Behring by Australian company CSL in 2004. He was Vice President and General Manager for Emerging Markets for Aventis Behring from 1996-2000 and served as President of Aventis BioServices from 2000-2004. Dr. Martinez began his career with Sandoz Ltd., today Novartis. He spent twenty years working with the company in a variety of roles across the world, such as Director and Head of Corporate Strategic Planning in the United States, Head of the Latin America Business Operations in Switzerland, Director of Marketing and Sales in Spain, and Head of Marketing and Clinical Research in Brazil. Dr. Martinez is originally from Brazil and holds an MD from the University of Sao Paulo.

 
Frederick J. Fritz
Image of Frederick J. Fritz
Frederick J. Fritz
Director
Director since 07/08/2011

Mr. Fritz is currently the CEO & Founder of NeuroDx, a development stage diagnostic device company focused on the neurosurgery market. Mr. Fritz joined NeuroDx from Valeo Medical, a biotech company he founded in 2003 to develop the world's first non-invasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, a medical device spin out of Sarnoff Corp. He is a University of Illinois engineer (summa cum laude) and a Harvard MBA. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough's Wesley Jessen in 1985 as VP Marketing and Sales in 1986. He was promoted to general manager of Schering's Over the Counter pharmaceutical business in 1988 and of the podiatric products business in 1990. He was President of Coleman North America from 1995-1997. He lives outside Princeton NJ with his wife, Helen, and two teenage daughters, Erika and Jenna.

   
Donald Braun Ph.D.
Image of Donald Braun Ph.D.
Donald Braun Ph.D.
Director
Director Since 12/15/2015

Dr. Braun joined Celsion in 2015 and brings over 30 years of research expertise in oncology, with a focus on immunotherapy and the effectiveness and impact of chemotherapy protocols on various cancers and tumor types. Prior to his retirement in 2016 Dr. Braun served as Vice President Translational Research and Chief Science Officer at the Cancer Treatment Centers of America. Prior to the CTCA, he was the Scientific Director of the Cancer Center and Professor of Medicine and Immunology at Rush Medical College in Chicago, and the Administrative Director of the Cancer Institute and a Professor of Surgery with tenure at the Medical College of Ohio.  Dr. Braun has been appointed to and served on more than a dozen federal government and public advisory committees on oncology and immunology. He received his Ph.D. in Immunology and Microbiology from the University of Illinois at the Medical Center in Chicago.

     
Andreas Voss MD
Image of Andreas Voss MD
Andreas Voss MD
Director
Director Since 12/15/2015

Dr. Voss joined Celsion in 2015 and currently serves as Vice President of Clinical Affairs in Europe at Caris Life Sciences, a biotechnology company focused on implementing personalized medicine in oncology through its liquid biopsy technology. Prior to joining Caris in 2010, he was responsible for the global clinical development of Avastin® and a member of the Corporate Drug Safety Board at F. Hoffmann-La Roche. Before joining Roche in 2006, he was Medical Director for the Lung Cancer Disease Area at AstraZeneca, and from 2000 to 2003, he was the Medical Director for Anti-infectives and Oncology atBayer GmbH.  From 1996 to 2000, Dr. Voss was Head of Medical Research, Oncology at Asta Medica AG. Dr. Voss received his M.D. from the University of Hamburg Medical School and was a postdoctoral fellow at the University of California at San Diego. He is board certified in internal medicine

     
= Chair = Member = Independent Director

Stock transaction information provided by EDGAR Online. Celsion Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Share This